FDA Drug · D-0926-2017

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Class III · Terminated

Superpotent Drug: high out-of-specification result for magnesium.

Affected lots / codes — check yours against thisLot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19

Recalling firm: Sanofi-Aventis U.S. LLC, Bridgewater, NJ
Classification: Class III (unlikely to cause harm)
Status: Terminated
Quantity: 2980 bottles
Distribution: Nationwide in the USA, Puerto Rico, and the United Kingdom.
Recall initiated: June 12, 2017
Classified: June 29, 2017
Terminated: February 7, 2019
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0926-2017%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →